Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

-- Orthocell (ASX:OCC) said results from an ongoing multi-center post-market clinical follow-up study for its nerve repair product, Remplir, showed an overall treatment success rate of nearly 90%, based on performance data from 66 patients, according to a Tuesday Australian bourse filing.

The company said over 90% of motor nerve repairs resulted in functional muscle recovery, while more than 89% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms.

The patients were aged 14 to 82 years, and the majority of the procedures were performed in the upper limb. No post-treatment complications or adverse effects were reported.

Orthocell's shares jump nearly 4% in recent trading on Tuesday.

Torque Metals公司稱，鑽探結果持續顯示西澳大利亞金礦項目礦化範圍擴大；股價下跌5%。

根據週二提交給澳洲證券交易所的文件，Torque Metals（ASX：TOR）在收到鑽探結果後，於3月份季度繼續擴大其位於西澳大利亞的Paris金礦床的礦化範圍，其中包括在222米深處發現20米厚、金品位為5.79克/噸的礦段。該公司表示，計劃進行更多鑽石鑽探，以便更好地確定該礦床新的高品位礦脈邊界，並計劃在第二季度更新Paris項目的礦產資源量中期估算。 Torque Metals在3月份季度末的現金餘額約為1220萬澳元，該公司表示，這使其擁有“雄厚的資本實力”，能夠支持正在進行的多鑽機鑽探作業。該公司股價在周二的交易中下跌了5%。

$ASX:TOR

哲尚證券第一季獲利成長35%，營收成長41%；股價上漲4%。

根據週二在上海證券交易所發布的公告顯示，浙商證券（SHA:601878）第一季歸屬於股東的淨利潤年增35%，從去年同期的5.556億元人民幣增至7.512億元人民幣。每股盈餘較去年同期成長42%，從上年同期的0.12元人民幣增至0.17元。營業收入較去年同期成長41%，從去年同期的16.8億元增加至23.6億元。週二午後交易時段，浙商證券股價上漲4%。

$SHA:601878

Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

相關文章

Torque Metals公司稱，鑽探結果持續顯示西澳大利亞金礦項目礦化範圍擴大；股價下跌5%。

傑富瑞將印度煤炭公司（Coal India）的目標股價從485印度盧比上調至500印度盧比，維持「買入」評級。

哲尚證券第一季獲利成長35%，營收成長41%；股價上漲4%。